The use of this inhibitor in combination with bevacizumab increases mice survival compared to bevacizumab alone suggesting that CCL2 suppression can increase the efficacy of anti-angiogenic treatments in GBM [119]. The gene discussed is CCL2; the disease is glioblastoma.